文献速递银屑病与炎症性皮肤病

巴西与智利的银屑病治疗可及性:一项横断面多中心全球银屑病医疗研究

Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis.
PubMed 文献 · Br J Dermatol · 2023-01-01

该研究在巴西和智利43个中心纳入1424例成人银屑病患者,采用48项问卷评估系统治疗可及性与保险报销。智利患者病情较巴西更重(PASI 11.6 vs 8.4,P<0.001)。中重度患者中生物制剂可及性不足,巴西37.0%、智利27.3%接受生物制剂(P=0.01)。

要点

  • 智利银屑病患者病情较巴西更重,PASI 11.6 vs 8.4(P<0.001)。
  • 中重度患者中仅37.0%巴西患者和27.3%智利患者接受生物制剂(P=0.01)。
  • 因缺乏可及性或保险报销无法获得生物制剂者,巴西22.2%、智利67.9%(P<0.001)。

核心结论

  • 本研究中智利银屑病患者病情显著重于巴西患者。
  • 两国中重度银屑病非生物制剂治疗可及,但包括生物制剂在内的更有效治疗可及性亟需改善。
  • 结果凸显国际银屑病指南推荐与巴西和智利现实情况之间存在显著差距。

研究设计与样本

  • 与全球银屑病地图集合作开展的横断面调查研究,2020年在巴西和智利进行。
  • 多中心全球银屑病医疗研究,共纳入43个中心1424例成人银屑病患者,巴西27个中心826例,智利16个中心598例。
  • 由医生和护士完成48项问卷,内容包括PASI、BSA、DLQI、系统治疗可及性和保险报销状态。
  • 连续变量采用Wilcoxon秩和检验,分类变量酌情采用χ2检验或Fisher精确检验。

主要发现

  • 未分层分析显示智利患者病情较巴西更重:PASI 11.6 vs 8.4(P<0.001),BSA 14.7 vs 12.0(P=0.003)。
  • 中重度银屑病(PASI和/或BSA≥10)患者中,非生物制剂系统药物可及:巴西81.2% vs 智利65.3%(P≤0.001)。
  • 中重度患者接受生物制剂的比例:巴西37.0% vs 智利27.3%(P=0.01)。
  • 中重度患者因缺乏可及性和/或保险报销而无法获得生物制剂:巴西22.2%(50/225) vs 智利67.9%(148/218)(P<0.001)。
  • 因缺乏可及性/保险报销无法获得生物制剂者,巴西中位PASI 9.15(IQR 3.00-14.25) vs 智利12.0(IQR 5.00-19.00)(P=0.007);中位BSA 7.0(IQR 3.00-15.00) vs 12.0(IQR 5.00-22.50)(P=0.002);中位DLQI 11.0(6.00-15.00) vs 21.0(6.50-25.00)(P=0.007)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sufficient data on access to systemic treatment for patients with psoriasis living in Latin America (LA) including Brazil and Chile are lacking. Understanding the availability and limiting factors of access to treatments can help to improve patient care and decrease long-term healthcare costs. OBJECTIVES: In association with the Global Psoriasis Atlas, this cross-sectional survey study analysed the availability and insurance reimbursement of systemic treatments for adult patients with psoriasis in Brazil and Chile. METHODS: A multicentre, cross-sectional Global Healthcare Study on Psoriasis was performed in Brazil and Chile in 2020. For each eligible adult patient with psoriasis, doctors and nurses completed a 48-item questionnaire about clinical aspects of psoriasis including the Psoriasis Area Severity Index (PASI), body surface area (BSA) score and the Dermatology Life Quality Index (DLQI), as well as the availability of systemic treatments and insurance reimbursement status. Between-country differences were compared with Wilcoxon rank sum tests for continuous variables, and a χ2-test or Fisher's exact test, where appropriate, for categorical variables. The median and interquartile range (IQR) was calculated for non-normal distributed data. RESULTS: A total of 1424 patients with psoriasis from 43 centres [27 centres in Brazil (n = 826) and 16 in Chile (n = 598)], were included with a mean (SD) age of 49.1 (16.3) and 49.2 (15.1) years, respectively. Unstratified analyses revealed that patients with psoriasis in Chile had more severe disease than those in Brazil [PASI 11.6 vs. 8.4 (P < 0.001) and BSA 14.7 vs. 12.0 (P = 0.003), respectively]. For patients with moderate-to-severe psoriasis, defined as PASI and/or BSA ≥ 10, systemic nonbiologic drugs were available (81.2% in Brazil and 65.3% in Chile, P ≤ 0.001), but only 37.0% of patients in Brazil and 27.3% in Chile received biologics (P = 0.01). Lack of availability and/or lack of insurance reimbursement for biologic drugs for patients with moderate-to-severe psoriasis was reported for 22.2% (50 of 225) in Brazil and 67.9% (148 of 218) in Chile (P < 0.001). Patients with no access to biologic therapies due to lack of availability/insurance reimbursement had a median PASI of 9.15 (IQR 3.00-14.25) in Brazil and 12.0 (IQR 5.00-19.00) in Chile (P = 0.007), as well as a median BSA of 7.0 (IQR 3.00-15.00) and 12.0 (IQR 5.00-22.50) (P = 0.002), and median DLQI of 11.0 (6.00-15.00) and 21.0 (6.50-25.00) (P = 0.007), respectively. CONCLUSIONS: Chilean patients had significantly more severe psoriasis compared with Brazilian patients in our study. While nonbiologic treatments for moderate-to-severe psoriasis were available in both LA countries, there is a high need for improvement in access to more effective psoriasis treatments including biologics. Our results highlight a significant gap between treatment recommendations in international psoriasis guidelines and real-world situations in Brazil and Chile.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Maul JT, Fröhlich F, Maul LV, et al. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol. 2023. PMID: 36653920. doi:10.1093/bjd/ljac128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。